SG11202108833QA - Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis - Google Patents

Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis

Info

Publication number
SG11202108833QA
SG11202108833QA SG11202108833QA SG11202108833QA SG11202108833QA SG 11202108833Q A SG11202108833Q A SG 11202108833QA SG 11202108833Q A SG11202108833Q A SG 11202108833QA SG 11202108833Q A SG11202108833Q A SG 11202108833QA SG 11202108833Q A SG11202108833Q A SG 11202108833QA
Authority
SG
Singapore
Prior art keywords
mast cell
duodenitis
compositions
gastroenteritis
esophagitis
Prior art date
Application number
SG11202108833QA
Inventor
Bradford Andrew Youngblood
Bhupinder Singh
Amol Kamboj
Simon Greenwood
Henrik Rasmussen
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of SG11202108833QA publication Critical patent/SG11202108833QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/062Gastritis or peptic ulcer disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7095Inflammation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
SG11202108833QA 2019-02-15 2020-02-14 Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis SG11202108833QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806604P 2019-02-15 2019-02-15
US201962925704P 2019-10-24 2019-10-24
PCT/US2020/018405 WO2020168271A1 (en) 2019-02-15 2020-02-14 Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis

Publications (1)

Publication Number Publication Date
SG11202108833QA true SG11202108833QA (en) 2021-09-29

Family

ID=72044142

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108833QA SG11202108833QA (en) 2019-02-15 2020-02-14 Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis

Country Status (12)

Country Link
US (1) US20220135673A1 (en)
EP (1) EP3923986A4 (en)
JP (1) JP2022520105A (en)
KR (1) KR20210126084A (en)
CN (1) CN113747918A (en)
AU (1) AU2020223365A1 (en)
BR (1) BR112021015009A2 (en)
CA (1) CA3130072A1 (en)
IL (1) IL285430A (en)
MX (1) MX2021009626A (en)
SG (1) SG11202108833QA (en)
WO (1) WO2020168271A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200270344A1 (en) * 2017-05-05 2020-08-27 Allakos Inc. Methods and compositions for treating inflammatory gastrointestinal disorders
SG11201910193VA (en) 2017-05-05 2019-11-28 Allakos Inc Methods and compositions for treating allergic ocular diseases
JP2022553378A (en) * 2019-10-24 2022-12-22 アラコス インコーポレイテッド Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
AU2021365008A1 (en) * 2020-10-22 2023-06-08 Allakos Inc. Anti-siglec-8 antibody formulations
CN116963775A (en) * 2021-03-03 2023-10-27 爱乐科斯公司 anti-SIGLEC-8 antibody formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2465873A1 (en) * 2010-12-16 2012-06-20 Deutsches Rheuma-Forschungszentrum Berlin Eosinophils as a therapeutic target
IL298470A (en) * 2013-12-09 2023-01-01 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
US20200270344A1 (en) * 2017-05-05 2020-08-27 Allakos Inc. Methods and compositions for treating inflammatory gastrointestinal disorders

Also Published As

Publication number Publication date
EP3923986A4 (en) 2022-10-12
BR112021015009A2 (en) 2021-10-05
AU2020223365A1 (en) 2021-08-26
IL285430A (en) 2021-09-30
WO2020168271A1 (en) 2020-08-20
CA3130072A1 (en) 2020-08-20
MX2021009626A (en) 2021-09-08
CN113747918A (en) 2021-12-03
JP2022520105A (en) 2022-03-28
EP3923986A1 (en) 2021-12-22
US20220135673A1 (en) 2022-05-05
KR20210126084A (en) 2021-10-19

Similar Documents

Publication Publication Date Title
IL285430A (en) Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
MX2020012028A (en) Methods and compositions for treating cancer.
JOP20210060A1 (en) Modulators of alpha-1 antitrypsin
MX2012011543A (en) Treatment of sarcoidosis using placental stem cells.
IL285886A (en) Compositions and methods for treating laminopathies
IL287981A (en) Compositions and methods for treating t cell exhaustion
WO2009124653A3 (en) Thienopyrimidines
EP3847283A4 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
EP4025590A4 (en) Methods and compositions for treating cancer
WO2011100642A3 (en) Method for treating hematological cancers
EP2035015A4 (en) Compositions, methods, and kits for treating dry eye
EP4077333A4 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IL286153A (en) Methods and compositions for treating cancer
WO2012061086A3 (en) Method of treating neuroendocrine tumors
EP4070810A4 (en) Method for treating cancer using artificial adjuvant vector cells (aavc)
EP3959199A4 (en) Compositions and methods for treating ras-mutant cancers
IL290834A (en) Compositions and methods for treating extensive stage small cell lung cancer (es-sclc)
EP4135760A4 (en) Compositions and methods for treating leukemia
IL307872A (en) Novel compositions and methods for treating coronavirus infections
AU2022300265A1 (en) Methods and compositions for treating gorlin syndrome
IL285796A (en) Methods and compositions for treating
GB202207363D0 (en) Methods for treating porous membranes
EP3976013A4 (en) Methods, compositions and devices for treating neuroinflammatory conditions
WO2018085527A3 (en) Amnion tissue grafts and methods of preparing and using same
EP4031253A4 (en) Methods and compositions for treating myc-driven cancers